Italy Peptide Receptor Radionuclide Therapy (PRRT) Market 2018: Competitive Landscape, Survey And Environmental Study Up To 2025 In Healthcare Sector

Peptide receptor radionuclide therapy (PRRT) is a type of molecular therapy, also known as radioisotope therapy that is used for treating neuroendocrine tumors. In this therapy, a peptide similar to the natural hormone is combined with radioactive material such as Yttrium and Lutetium, to produce radionuclide which is then injected into the patient’s body. This combination binds to the neuroendocrine tumors in the body. It is a cell targeting type of therapy since it delivers a high dose of radiation directly to the tumor cells.

Key player operating in the Italy Peptide Receptor Radionuclide Therapy (PRRT) Market is Novartis International AG.

Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/3139

Market Dynamics

Rising number of cancer cases in Italy is expected to drive the Italy peptide receptor radionuclide therapy (PRRT) market growth during the forecast period. For instance, as per data published by the Epidemiology Unit, Agency for Health Protection of Milan, Corso Italia, in 2012- 2015, 3,803 patient diagnosed with colorectal cancer. Cancer patients in the age group below 50 years accounted for 22.25%, of the total cancer cases that were reported and patients in the age group of 50 to 64 years accounted for 17.65%, and patients over the age of 65 accounted 20.80%.

Furthermore, according the WHO, in 2018, around 43,837 cases of prostate cancer were reported, which contributed around 10% of the total cancer cases recorded in Italy.

However, side effects associated with peptide receptor radionuclide therapy may negatively impact growth of the peptide receptor radionuclide therapy market. The side effects occur on the body part which is treated with radiation. Some of the common side effects faced by patients undergoing radiation therapy are nausea, vomiting, abdominal discomfort or pain, and in some cases, temporary hair loss and sub-acute hematology toxicity. Hence, this may hamper the Italy peptide receptor radionuclide therapy market growth.

Increasing incidence of pancreatic cancer, as well as availability of reimbursement for cancer drug is another factor contributing to the market growth.

Increasing incidence of pancreatic cancer in Europe region is expected to support growth of the market over the forecast period. For instance, according to United European Gastroenterology report in Europe region, there was a 5% increase in the number of pancreatic cancer cases during the years 1990 to 2016.

The European Medicines Agency (EMA) plays a central role in facilitating development and authorization of medicines for rare diseases, which are termed as ‘orphan medicines’. In Italy, prices of ODs (Orphan Drugs) and reimbursement by the National Health Service is set through negotiation between the Italian Medicines Agency (AIFA), and pharmaceutical companies. Reimbursement of 38% is available for ODs in Italy which includes peptide receptor radionuclide therapy (PRRT).

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market - Restraints

High cost associated with cancer treatment, which include diagnosis and therapeutic treatment, is a major factor that is expected to restrain growth of the market. For instance, as per the Economist Intelligence Unit Limited’s 2016 report, lung cancer treatment cost has become a burden on the economy in Italy. In 2013, it was estimated that total cost for treatment of lung cancer reached around US$ 18.31 billion.

Currently, only one approved PRRT drug is available in the Italy market, and is used in the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumor (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Therefore, lack of availability of different drugs is another major factor restraining growth of the market.

Moreover, high cost of treatment is expected to restrain growth of the market. For instance, Novartis Company’s drug, Lutathera, is priced at US$ 99,900 for a full course of treatment comprising four infusions.

You Can Purchase Complete Report To Grow Your Business @ https://www.coherentmarketinsights.com/insight/buy-now/3139

Detailed Segmentation:

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, by Drug Type:
Lutetium (Lu-177)-based
Yttrium (Y-90)-based
Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, by Indication
Gastroenteropancreatic Neuroendocrine Tumor
Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Company Profiles
Novartis International AG *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.